These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Modifications of platelet retention in patients treated with pyridinolcarbamate. A preliminary report. Girolami A, Peruffo R, Emanueli A. Arzneimittelforschung; 1977; 27(6):1202. PubMed ID: 578441 [Abstract] [Full Text] [Related]
23. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans. Roztocil K, Oliva J, Linhart J, Prerovský I, Modr Z. Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932 [Abstract] [Full Text] [Related]
24. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities. Hunyi L. Ther Hung; 1978 Mar; 26(2):77-80. PubMed ID: 684660 [No Abstract] [Full Text] [Related]
26. [Changes of the electrophoretic tracing of the serum glycoproteins in diabetic subjects treated with pyridinolcarbamate]. Notarbartolo A, Rini GB, Di Fede G. Boll Soc Ital Cardiol; 1973 Mar; 18(4):379-83. PubMed ID: 4807078 [No Abstract] [Full Text] [Related]
29. [Changes of the blood kallikrein-kinin system in patients with diffuse toxic goiter under the influence of thyrostatic therapy and prodectin]. Matiashina GI. Vrach Delo; 1989 Apr; (4):31-3. PubMed ID: 2474220 [Abstract] [Full Text] [Related]
30. [Thermal test of reactive hyperemia: a propos of an objective study of pyridinol carbamate]. Lauliac M. Phlebologie; 1978 Apr; 31(2):119-29. PubMed ID: 693585 [Abstract] [Full Text] [Related]
33. [Current trends in the therapy of arteriosclerotic disease]. Toscano S. G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524 [No Abstract] [Full Text] [Related]
34. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications. Abrányi I, Máté. Ther Hung; 1976 Jan; 24(1):20-3. PubMed ID: 790631 [No Abstract] [Full Text] [Related]